Quantitative Systems Pharmacology Modeling Provides Insight into Inter-mouse Variability of Anti-CTLA4 Response

Collaboration with Pfizer - Published in CPT:Pharmacometrics & Systems Pharmacology

Two heads are better than one: current landscape of integrating QSP and machine learning

Published in the Journal of Pharmacokinetics and Pharmacodynamics

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid

Collaboration with Biogen - Published in CPT: Pharmacometrics Systems Pharmacology

Mathematical Approaches for Predicting Risks Early-On in Drug R&D

Published in Pharma Tech Outlook Magazine

A systems pharmacology model for gene therapy in sickle cell disease

Collaboration with CSL Behring - Published in CPT: Pharmacometrics Systems Pharmacology

Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer

Collaboration with Astellas Pharma - Published in CPT: Pharmacometrics & Systems Pharmacology

Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease

Published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association


Despite strong evidence linking amyloid beta (Aβ) to Alzheimer's disease, most clinical trials have shown no clinical efficacy for reasons that remain unclear. To understand why, we developed a quantitative systems pharmacology (QSP) model for seven therapeutics: aducanumab, crenezumab, solanezumab, bapineuzumab, elenbecestat, verubecestat, and semagacestat.

Quantitative modeling predicts competitive advantages of a next generation anti‐NKG2A therapy over monalizumab for the treatment of cancer

Collaboration with KSQ Therapeutics - Published in CPT: Pharmacometrics Systems Pharmacology

Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072

Collaboration with CytomX Therapeutics - Published in Clinical Pharmacology & Therapeutics


CX‑072 is an anti‑PD‑L1 (programmed death ligand 1) Probody therapeutic (Pb‐Tx) designed to be preferentially activated by proteases in the tumor microenvironment and not in healthy tissue. Here, we report the model‐informed drug development of CX‐072. A quantitative systems pharmacology (QSP) model that captured known mechanisms of Pb‐Tx activation, biodistribution, elimination, and target engagement was used to inform clinical translation.

Mechanistic PKPD Models of Protein Therapeutics for Early Clinical Development


Mechanistic PKPD models support FIH trial design, development of targeted immunotherapies, and understanding complex PK properties and covariates.